Product
Eculizumab
Aliases
Soliris
19 clinical trials
29 indications
Indication
Paroxysmal Nocturnal HemoglobinuriaIndication
Myasthenia GravisIndication
Juvenile Myelomonocytic LeukemiaIndication
GeneralizedIndication
Guillain-Barre SyndromeIndication
Kidney TransplantIndication
Hemolytic Uremic SyndromeIndication
atypicalIndication
PreeclampsiaIndication
preeclampsiaIndication
eculizumabIndication
HELLPIndication
HELLP SyndromeIndication
Third TrimesterIndication
Complement AbnormalityIndication
MorbidityIndication
Maternal InjuryIndication
Preeclampsia SevereIndication
HELLP syndromeIndication
Pregnancy RelatedIndication
PNHIndication
Complement Regulatory Factor DefectIndication
Thrombotic MicroangiopathyIndication
Atypical Hemolytic Uremic SyndromeIndication
Multiple Organ Dysfunction SyndromeIndication
Neuromyelitis OpticaIndication
Neuromyelitis Optica Spectrum DisorderIndication
Atypical Hemolytic UremicClinical trial
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.Status: Active (not recruiting), Estimated PCD: 2022-11-16
Clinical trial
An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia GravisStatus: Completed, Estimated PCD: 2022-01-06
Clinical trial
A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor TherapyStatus: Terminated, Estimated PCD: 2023-09-14
Clinical trial
A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody.Status: Completed, Estimated PCD: 2022-09-26
Clinical trial
A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamic And Efficacy of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsStatus: Recruiting, Estimated PCD: 2029-09-01
Clinical trial
Open-Label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaStatus: Active (not recruiting), Estimated PCD: 2025-06-13
Clinical trial
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabStatus: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or RavulizumabStatus: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Completed, Estimated PCD: 2018-01-25
Clinical trial
A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Completed, Estimated PCD: 2022-07-12
Clinical trial
A Single Center, Open-label, Single-arm Study to Determine the Safety and Efficacy of a Single Dosing Regimen Eculizumab for Prevention of Antibody-Mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi-LDKTx)Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring: Prospective Health-economic Evaluation in Patients in Remission With Atypical Hemolytic Uraemic Syndrome Requiring Long-term Treatment.Status: Active (not recruiting), Estimated PCD: 2023-12-28
Clinical trial
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH StudyStatus: Terminated, Estimated PCD: 2021-12-07
Clinical trial
Early Intervention With Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome (TMA/aHUS)-Associated Multiple Organ Dysfunction Syndrome (MODS) in Hematopoietic Stem Cell Transplant (HCT) RecipientsStatus: Completed, Estimated PCD: 2022-04-04
Clinical trial
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum DisorderStatus: Terminated, Estimated PCD: 2023-07-31
Clinical trial
Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment-Naïve Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in ChinaStatus: Recruiting, Estimated PCD: 2026-03-31